ModifiedUnitedHealthcarePolicy CS334ID.B

Prostate Surgeries and Interventions (for Idaho Only)

This policy governs medical necessity and coverage determinations for prostate surgeries and minimally invasive prostate interventions for UnitedHealthcare members in Idaho (including Idaho Medicaid Plus). It specifies which procedures are considered proven/medically necessary versus unproven/not medically necessary and references InterQual criteria for clinical details.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Idaho Only)

Policy CodePolicy CS334ID.B

Change TypeCoverage clarifications & coding updates

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionReference updated applicable procedure codes and remove CPT 55874 from prior authorization and billing submissions.

SourceLink

POLICY UPDATE CHANGES

Removed coverage criteria for transperineal placement of biodegradable material.

Revised coverage criteria for prostatic urethral lift to specify 'including lateral, with or without median lobe hyperplasia, in men 45 years of age or older'.

Clarified transurethral water jet ablation is unproven and not medically necessary for treatment of malignant prostate tissue and other non-proven indications due to insufficient evidence of safety and/or efficacy.

Reworded prostate artery embolization (PAE) coverage to specify it is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints or anesthesia risk.

Added transurethral thermal ultrasound ablation (TULSA) to the list of unproven and not medically necessary procedures.

Added CPT codes 51721, 53865, 53866, 55881, and 55882 to applicable codes; removed CPT code 55874.

05/01/2026Policy effective

RevisedPAE coverage clarified

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

TULSANew unproven procedure

Coverage Criteria and Clinical Conclusions

Revised Indications

Revised Indications — Summarized coverage clarifications and updates:

Prostatic urethral lift (PUL/UroLift): Coverage criteria revised to specify treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral, with or without median lobe hyperplasia, in men 45 years of age or older; other specific contraindications and device labeling (e.g., prostate volume >100 cc, active urinary tract infection, urethral conditions preventing device insertion, urinary incontinence due to incompetent sphincter, current gross hematuria) remain exclusionary.

Transurethral water jet ablation: Language clarified to state transurethral water jet ablation is proven and medically necessary when used for resection/removal of prostate tissue to treat lower urinary tract symptoms (LUTS) due to BPH; use for treatment of malignant prostate tissue and all other indications not listed as proven in the policy is unproven and not medically necessary due to insufficient evidence.

Prostate artery embolization (PAE): Wording refined to indicate PAE is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., very large prostate size) or anesthesia risk/comorbidities. PAE remains unproven for other indications.

Transperineal placement of biodegradable material: Coverage criteria removed.

Other procedures: The list of procedures considered unproven/not medically necessary was updated to add transurethral thermal ultrasound ablation (TULSA) and to consolidate other procedures lacking sufficient evidence (e.g., TPLA, magnetic induction ablation, transperineal focal laser ablation, temporary prostatic urethral stents, transurethral drug-coated balloon for indications beyond listed proven uses).

CPT code removals/additions: CPT code 55874 was removed from the policy; applicable code lists were updated to reflect addition of codes (e.g., 51721, 53865, 53866, 55881, 55882) and removal of 55874.

Procedure-specific coverage stances

Procedure-specific coverage stances — Coverage determinations and supporting clinical conclusions for specified procedures:

Transurethral ablation (TURP/other transurethral modalities): Proven and medically necessary in certain circumstances; for clinical medical necessity criteria, refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Cryoablation: Proven and medically necessary for recurrent prostate cancer diagnosed by biopsy as salvage therapy per InterQual criteria; cryoablation for initial treatment of prostate cancer and for other indications is unproven and not medically necessary.

Prostatic urethral lift (PUL/UroLift): Proven and medically necessary when performed according to FDA labeled indications for treating LUTS due to BPH in men ≥45 years with prostate volume and anatomic constraints as specified; unproven for other indications.

High-energy water vapor thermotherapy (Rezūm): Proven and medically necessary in circumstances meeting InterQual criteria for BPH; use for malignant prostate tissue and other non-approved indications is unproven and not medically necessary.

Applicable Procedure and Billing Codes

Note

Provider notice

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non‑covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Prior authorization/coverage determinations should reference the listed applicable procedure codes; inclusion of codes does not guarantee coverage. Documentation supporting medical necessity should be legible, maintained in the patient’s medical record, and must be made available upon request.

Provider action: Applicable procedure codes (reference).
Provider action: Documentation supports medical necessity — medical records required and must be available upon request.
Provider action: Reference current policy version for code updates and coverage rules.

Prior Authorization

Prior Authorization Required

Prior authorization is required for procedures covered under this policy when performed for the limited FDA‑labeled indications noted in the policy. Authorization (PAE) decisions require clinical eligibility documentation and expected outcome measures supporting medical necessity.

Provider Steps, Prior Authorization, and Documentation

Prior Authorization

PAE prior authorization may be required

When PAE is proposed as an alternative to established surgical options, prior authorization review may be required because comparative evidence vs TURP/open procedures is limited and additional documentation to justify selection of PAE may be requested.

Prior Authorization

Require documentation that PAE is for patients ineligible for established surgery

Prior authorization for PAE should include evidence that the patient is not a candidate for established surgical therapies (e.g., TURP/open prostatectomy) or that the procedure is intended for control of persistent gross prostatic hematuria; include the clinical rationale for selecting PAE.

Document reason the member is a poor surgical candidate (frailty, anesthetic risk, prostate size) or evidence of refractory gross hematuria
Include documentation of counseling about alternative therapies and retreatment risks

Prior Authorization

Include trial-based eligibility and outcome data in prior authorization

Background and Rationale

Benign prostatic hyperplasia (BPH) is the most common prostate problem in men over age 50 and can cause symptoms such as urinary retention, weak urinary stream, urgency, and difficulty initiating urination. Management ranges from conservative measures and medications for mild disease to minimally invasive procedures and surgical interventions for patients who fail or cannot tolerate medical therapy.

Definitions and Device/Procedure Descriptions

Cryoablation — definition and short description

DefinitionCryoablation (cryoablation/cryotherapy) uses transrectal ultrasound–guided probes inserted via the perineum; very cold gas is passed through probes to freeze and destroy prostate tissue.

Typical useDescribed for recurrent prostate cancer and discussed in outcomes literature; not recommended as initial definitive therapy for prostate cancer in many indications.

GuidanceEvidence is heterogeneous and primarily observational, limiting conclusions about long‑term oncologic effectiveness and functional outcomes.

High‑energy water vapor thermotherapy (Rezūm) — definition

DefinitionHigh‑energy water vapor thermotherapy (Rezūm) uses thermal water vapor to reduce prostate volume associated with BPH, including central zone and middle lobe hyperplasia.

Regulatory note

Policy History and Revisions

2026-05-01code_additionLatest

Added CPT codes 51721, 53865, 53866, 55881, and 55882 to the policy's applicable codes.

2026-05-01code_removal

Removed CPT code 55874 from the policy's applicable codes (code no longer listed as applicable).

2026-05-01supporting_section_update

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Idaho Only)

Policy CodePolicy CS334ID.B

Change TypeCoverage clarifications & coding updates

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionReference updated applicable procedure codes and remove CPT 55874 from prior authorization and billing submissions.

SourceLink

On This Page

Transurethral water jet ablation (Aquablation): Proven and medically necessary for resection/removal of prostate tissue to treat LUTS due to BPH based on randomized trial evidence demonstrating durable symptom and flow improvements versus TURP; unproven for treatment of malignant prostate tissue and other non-listed indications.

Prostate artery embolization (PAE): Considered proven and medically necessary for patients with BPH who are not candidates for established surgical therapies due to surgical/anesthesia risk or prostate size limitations, and for persistent gross hematuria originating from the prostate; routine replacement of TURP/open prostatectomy for otherwise suitable surgical candidates is not supported by current evidence—PAE remains investigational/conditionally considered when potential tradeoffs (short-term safety advantages vs inferior long-term functional outcomes and higher retreatment rates) are acceptable and patients are counseled accordingly.

Transperineal focal laser ablation / Transperineal laser ablation (TPLA)/Focal therapies: Considered unproven and not medically necessary for routine use in localized prostate cancer; current evidence is limited, heterogeneous, and lacks robust comparative long-term oncologic outcomes—use should be limited to clinical trials or prospective registries.

Temporary implanted prostatic devices (e.g., iTind), transurethral drug-coated balloon (Optilume), and other minimally invasive devices: Evidence varies by device; some (e.g., Optilume) have randomized sham-controlled data showing symptom improvement but lack long-term comparative data versus established therapies—use beyond listed proven indications is considered investigational or limited pending further evidence.

Transurethral thermal ultrasound ablation (TULSA) and ablation by magnetic field induction: Insufficient high-quality comparative evidence and thus considered unproven and not medically necessary for routine clinical use outside of research settings.

General conclusion on newer/alternative modalities: Procedures with insufficient evidence regarding long-term effectiveness, safety, or comparative benefit (including TPLA, magnetic induction ablation, certain temporary stents, drug-coated balloons for non-listed indications, and TULSA) are categorized as unproven/not medically necessary; select modalities (PUL, Aquablation, water vapor therapy, PAE in select patients) have conditional or proven roles when meeting device labeling, InterQual criteria, or specified patient-selection constraints.

Provider action: PAE — authorization of procedure for limited indications.
Provider action: Prior authorization: clinical eligibility and outcome documentation.
Provider action: Clinical evidence and outcome measures must be provided with the PAE request.

Documentation Required

Documentation that should be available on request includes: complete medical records, prior treatment history, documentation of symptoms and severity (e.g., IPSS), prostate volume measurement, imaging and staging results, trial of and response to medical therapy, and informed consent discussing alternative therapies and risks.

Provider action: Medical records required — documentation availability.
Provider action: Recommended documentation for PAE candidate: IPSS, prostate volume, imaging, prior medical therapy, trial details, and outcomes.
Provider action: Required clinical measurements: prostate volume (note: PUL contraindication if >100 cc).
Provider action: Pre‑procedure imaging and staging must be provided where applicable.

Denial Risk

Billing/Coding Risks

Claims billed using CPT code 55874 (previously used for certain thermal procedures) should be checked; note that CPT 55874 has been removed from the applicable code list and may trigger denial if billed for procedures no longer described by the policy. Coding mismatches between submitted claims and prior authorization documentation may trigger denial.

Provider action: Removed CPT code — check authorization (55874 removed).
Provider action: Removed CPT code denial risk — denial risk for removed indications and removed procedure code triggers denial risk.
Provider action: Coding mismatch may trigger denial; ensure codes on claim match those authorized and documented.

Denial Risk

Evidence and Coverage Risk

Insufficient comparative evidence may lead to PAE denial for non‑labeled indications or when evidence suggests inferiority to established therapies (e.g., TURP). Routine PAE for indications without adequate evidence carries a potential coverage denial risk.

Provider action: Insufficient comparative evidence (PAE) — include justification and outcome expectations.
Provider action: Potential coverage denial risk for routine PAE when evidence is insufficient.
Provider action: Insufficient evidence / inferiority risk relative to established therapies (document step to established therapy).

Note

FDA and Device Information

Provider action: Device approvals and FDA clearances are informational only and do not by themselves determine coverage. When device use is cited in support of a request, include device approval documentation and device‑specific labeling as part of the PAE submission.

Provider action: FDA clearance of a device is information; include device approval documentation when applicable.
Provider action: Device approval documentation and MRI/eligibility screening (trials required) should be included when relevant to the procedure.
Provider action: No step therapy rules are stated in this policy; however guidelines recommend discussing alternative therapies with the patient.

Applicable CPT Codes (neutral)CPT

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed MRI
0739T	Ablation of malignant prostate tissue by magnetic field induction, including intraprocedural needle/catheter placement and temperature monitoring
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation

1–10 of 21

1/3

Applicable CPT Codes (neutral continued)CPT

0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional implant
53850	Transurethral destruction of prostate tissue; by microwave thermotherapy
53852	Transurethral destruction of prostate tissue; by radiofrequency thermotherapy
53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy
53855	Insertion of a temporary prostatic urethral stent, including urethral measurement

1–10 of 11

1/2

Note

FDA product codes referenced

FDA product codes and device clearance information are informational only and do not determine coverage. When device use is cited, submit device-specific documentation with the PAE request.

Provider action: FDA clearance of a device is information; include device approval documentation when applicable.
Provider action: Device approval documentation should be included for PAE and stored in the medical record.

Billing Rule

Code Update Notice

Code list updates — added and removed CPT codes related to policy revision. Providers must ensure prior authorization and claims use the current codes. Documentation must justify use of any newly added code and explain why removed codes are not applicable.

Provider action: Updated applicable CPT codes — see Added/Removed lists below.
Provider action: Added applicable CPT codes require documentation to support medical necessity.
Provider action: Removed CPT triggers — removed CPT code (55874) may result in claim denial if used.

Added CPT Codes (covered)CPTCovered

51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation
53865	Cystourethroscopy with insertion of temporary device for ischemic remodeling of bladder neck and prostate
53866	Catheterization with removal of temporary device for ischemic remodeling of bladder neck and prostate
55881	Ablation of prostate tissue, transurethral, using thermal ultrasound, including MRI guidance and monitoring
55882	Ablation of prostate tissue, transurethral, using thermal ultrasound; with insertion of transurethral ultrasound transducer

Removed CPT Codes (not_covered)CPTNot Covered

55874

(Removed) Ablation of prostate tissue, transurethral, thermal procedure — removed from applicable code list

Documentation Required

Policy History / Documentation Alignment

Documentation alignment and policy history: the policy history documents that the following CPT codes were added and code 55874 was removed. Update authorization and billing documentation to reflect these revised sections. Medical records must be available and align with the indications and required measurements.

Provider action: Policy history notes that the patient's medical record must be available upon request.
Provider action: Policy history indicates updates to Description of Services, Clinical Evidence, FDA, and References; update documentation to reflect revised sections.
Provider action: Documentation availability — ensure records and device approval documents are filed and accessible.

Prior Authorization

PAE Submission Requirements

When requesting authorization, include: clinical presentation, prior therapies tried (including duration and response), prostate volume measurement, IPSS or other symptom scores, imaging/staging reports, device approval or labeling if applicable, and a clear statement of expected benefit and outcome measures.

Provider action: Prior authorization: include clinical eligibility and outcome documentation.
Provider action: Recommended documentation for PAE candidate: IPSS score, prostate volume, imaging, prior medical therapy and trial details, and expected outcomes.
Provider action: Trials required/MRI eligibility screening — include MRI or other imaging if procedure relies on imaging guidance.

Denial Risk

Denial Conditions

Failure to provide the requested documentation, use of removed CPT codes, or mismatch between PAE request and submitted claim may result in denial of authorization or claim payment. If a procedure is performed without prior authorization when required, claims may be denied.

Provider action: Denial risk for removed indications and removed procedure code triggers denial risk.
Provider action: No specific step therapy rules are stated in this policy; however, if TURP or other established therapy is indicated, documentation should show why less invasive options are appropriate.
Provider action: Claims billed using CPT code 55874 may be denied; check authorization and update claims coding as needed.

Prior authorization submissions should include trial-derived clinical eligibility and outcome measures commonly used in pivotal studies: patient age, baseline IPSS, peak urinary flow rate (Qmax), prostate volume, absence of disqualifying anatomy, and available follow-up outcome data to support expected benefit.

Baseline IPSS and Qmax values
Prostate volume (imaging) and absence/presence of obstructive median lobe
Available perioperative and follow-up IPSS/QoL and objective measures

Documentation Required

Document pre-procedure imaging and staging when applicable

When trials required MRI compatibility or other pre-procedure assessments, prior authorization requests should document relevant imaging and staging information (ability to undergo MRI, prior biopsy/PSA/staging) where applicable to the procedure.

Document MRI compatibility if required by the device/protocol
Provide prior biopsy results, PSA, and staging information when relevant

Prior Authorization

Check policy for procedures that may require prior authorization

Certain procedures described in the policy (for example, PAE consistent with covered indications) may require prior authorization or review; check the policy and payer-specific authorization procedures before submitting requests.

Billing Rule

Update prior authorization systems for newly added CPT codes

Policy history added CPT codes 51721, 53865, 53866, 55881, and 55882 to the Applicable Codes list; prior authorization and billing systems should be updated to account for these additions.

Added CPT codes: 51721, 53865, 53866, 55881, 55882

Prior Authorization

Use the policy’s updated applicable CPT code list for authorizations

Providers should reference the updated Applicable CPT code list (including 51721, 53865, 53866, 55881, 55882) when submitting prior authorization requests to ensure correct coding and authorization handling.

Prior Authorization

Verify prior authorization requirements for newly listed CPT codes

The policy added several CPT codes to the Applicable Codes list; providers should verify whether these specific codes require prior authorization under the main policy before billing or requesting approval.

Verify prior authorization requirements for CPT codes: 51721, 53865, 53866, 55881, 55882

Billing Rule

Remove CPT 55874 from prior authorization submissions

Prior authorization and coding processes should no longer reference CPT code 55874, which was removed from the policy’s applicable codes; update authorization submissions and internal code lists accordingly.

Denial Risk

Do not use removed CPT code 55874 for authorization or claims

CPT code 55874 has been removed from the policy’s Applicable Codes list; providers must review current authorization and billing rules and avoid using 55874 when submitting claims for covered procedures.

Do not bill or request authorization using CPT 55874 following its removal

Billing Rule

Update prior authorization processes to exclude CPT 55874

Prior authorization and coding processes should be updated to reflect removal of CPT 55874 from the policy; ensure submission systems and claim edits are aligned with the current Applicable Codes.

Prior Authorization

Check prior authorization requirements for codes added in policy history

Policy history shows the Applicable Codes list was updated to add CPT codes 51721, 53865, 53866, 55881, and 55882; check the main policy for any authorization requirements associated with these added codes.

Billing Rule

Ensure authorization and coding reflect added and removed CPT codes

Prior authorization and coding workflows must account for the newly added CPT codes and the removal of 55874; confirm that authorizations, claim edits, and internal code lists reflect these changes.

Billing Rule

Verify prior authorization submissions use the updated CPT code set

The policy update states CPT codes 51721, 53865, 53866, 55881, and 55882 were added and CPT 55874 removed; verify authorizations and billing submissions use this updated code set.

Step Therapy

Document consideration of established surgical therapy before newer procedures

Given comparative trial results favoring TURP for some efficacy endpoints, prior authorization may expect documentation that standard surgical options (e.g., TURP) were considered before approving newer or minimally invasive procedures.

Document consideration of TURP and reasons for selecting a minimally invasive alternative
Include trial-relevant objective measures if available

Step Therapy

Document prior medical therapy trial before PAE

Authorization for PAE should include documentation of prior medical management (e.g., trials of alpha blockers) and evidence of failure or intolerance to medical therapy when applicable.

Document prior pharmacologic treatment and response/intolerance
Include objective measures showing persistent symptoms despite medical therapy

Step Therapy

Document failure or contraindication to TURP when requesting TPLA

Because randomized trials have shown TURP superiority on some endpoints, prior authorization for TPLA or similar alternatives may require documentation of failure or contraindication to TURP when relevant.

Document why TURP is contraindicated or was unsuccessful where applicable
Provide trial-based objective measures comparing expected outcomes

Documentation Required

Discuss and document standard therapy alternatives before experimental procedures

Clinical guidelines recommend discussing alternative standard therapies (e.g., radical prostatectomy, radiation, active surveillance) with patients prior to recommending experimental or less-established ablation procedures; document these discussions when relevant.

Documentation Required

Keep legible, complete medical records and make them available upon request

Maintain legible medical records that fully support medical necessity for requested services, including relevant history, exam, diagnostic test results, and make records available upon request for coverage review.

Include history of present illness and relevant comorbidities
Attach diagnostic imaging, IPSS/Qmax/PVR values, and prior treatment notes

Documentation Required

Supply clinical evidence and outcome measures to support requests

Provide clinical trial evidence and outcome measures when relevant to support medical necessity (RCTs, IPSS/Qmax, prostate volume) and include available follow-up data from prior studies up to reported durations when applicable.

Include RCT outcomes or systematic review summaries if used to justify treatment choice
Attach follow-up IPSS/Qmax and retreatment data when available

Documentation Required

Document comprehensive clinical rationale for PAE in poor surgical candidates

For PAE candidates who are poor surgical candidates, include documentation of prior medical management attempts, specific comorbidities or ASA score indicating surgical ineligibility, prostate imaging/volume, baseline IPSS and objective measures (Qmax, PVR), and history of catheter dependence if applicable.

Prior pharmacologic treatment history
ASA score or specific comorbid conditions making surgery high risk
Baseline imaging and objective voiding measurements

Documentation Required

Include required clinical measurements (IPSS, Qmax, prostate volume) in submissions

Include baseline and perioperative clinical measurements in authorization requests: baseline IPSS, Qmax, prostate volume, documentation of prior treatments, and perioperative/postprocedure IPSS and quality-of-life follow-up when available.

Baseline IPSS and Qmax
Prostate volume from imaging
Perioperative and follow-up IPSS/QoL measurements

Documentation Required

Document MRI eligibility and required pre-procedure assessments when applicable

Trials for some modalities (e.g., TULSA) required ability to undergo MRI and pre-procedure assessments such as cystoscopy; include documentation of MRI compatibility and relevant pre-procedure diagnostic workup when applicable.

Evidence of MRI compatibility and prior MRI reports
Records of prior biopsy, PSA, and cystoscopy when required

Note

Include device approval/clearance details when relevant (informational)

Device-specific FDA clearance or approval information is noted in the policy for informational purposes; include device identifiers or clearance documentation if relevant, but FDA clearance alone does not establish coverage.

Provide device name and FDA product code when applicable
Attach device clearance/approval references if relied upon in the request

Documentation Required

Ensure medical records fully document medical necessity and are available

Ensure medical records fully support medical necessity (history, exam, diagnostic results, device information) and that documentation is legible, maintained in the patient record, and available upon request for review.

Documentation Required

Make documentation legible, retained in record, and available on request

Documentation supporting medical necessity must be legible, maintained in the patient’s medical record, and made available upon request; failure to provide such documentation may lead to denial or inability to assess claims.

Documentation Required

Update documentation to align with revised policy sections

Policy revisions require updating documentation to align with revised Description of Services, Clinical Evidence, FDA, and References sections; ensure submitted records reflect current policy language and evidence where relevant.

Documentation Required

Reference the current policy version when preparing submissions

Reference and rely on the current policy version (CS334ID.B) when preparing authorization requests and documentation; prior archived versions are for historical context only.

Documentation Required

Ensure submission documentation aligns with updated policy sections

Ensure documentation aligns with the updated Description of Services, Clinical Evidence, FDA, and References sections noted in the policy history to avoid discrepancies during review.

Documentation Required

Reflect revised clinical evidence and service descriptions in documentation

Update clinical documentation to reflect the revised Description of Services and current clinical evidence cited in policy revisions when those revisions affect the requested service.

Documentation Required

Maintain and produce medical records upon request to avoid review delays

Maintain the patient’s medical record and make it available upon request for coverage review; inability to produce records on request may trigger review or denial.

Denial Risk

Denial risk: insufficient or missing medical record documentation

Failure to provide legible documentation of medical necessity (history, exam, diagnostic test results) may result in denial or inability to determine whether policy clinical criteria are met.

Denial Risk

Denial risk: routine PAE without evidence patient is poor surgical candidate

Because evidence is insufficient relative to standard treatments, requests for routine PAE as an alternative to TURP may be denied or require additional documentation unless the patient is clearly a poor surgical candidate.

Denial Risk

Denial risk: procedures lacking comparative evidence or shown inferior to standard care

Procedures with insufficient long-term comparative evidence or shown inferior to standard treatments (for example TPLA vs TURP) risk denial when submitted as equivalent alternatives without supporting comparative data.

Denial Risk

Denial risk: relying on FDA clearance alone for coverage

FDA clearance or approval of a device is informational only and does not by itself justify coverage; relying solely on device clearance without meeting policy coverage criteria may result in denial.

Denial Risk

Denied claims risk if CPT 55874 is used (code removed)

Billing or authorization using CPT code 55874 may be denied because CPT 55874 was removed from the policy’s Applicable Codes list; providers must use the current applicable codes when submitting claims or prior authorization requests.

Do not submit claims or authorizations using CPT 55874 after its removal

Denial Risk

Removed CPT code 55874 may trigger claim denials

Claims using the removed CPT code 55874 are no longer supported by the policy and may be denied; providers must update billing to the policy’s current applicable CPT codes.

Denial Risk

Coding mismatch (use of removed CPT 55874) can trigger denial

Using a removed CPT code (55874) in claims or authorization requests may trigger denial due to coding mismatch; ensure all submissions use the policy’s updated applicable codes.

Denial Risk

Failure to provide records on request may cause denial or review delay

Make the patient’s medical record available upon request for coverage review; lack of documentation or refusal to provide records may lead to review delays or denial.

Rezūm System is FDA‑cleared for treatment of symptoms of BPH and for treatment of prostate with central zone or median lobe hyperplasia (not approved for malignant prostate tissue).

Evidence notePolicy notes limited peer‑reviewed original data for some high‑energy water vapor uses when applied to malignant tissue; only established BPH indications are supported.

Transurethral water jet ablation (Aquabeam) — definition

DefinitionTransurethral water jet ablation (Aquabeam) is a heat‑free water‑jet system delivered transurethrally (AquaBeam Robotic System) to ablate benign prostate tissue.

IndicationUsed to treat lower urinary tract symptoms (LUTS) due to BPH; randomized trials compare Aquablation to TURP with follow‑up through 5 years.

Policy clarificationUnproven and not medically necessary for malignant prostate tissue and other non‑proven indications beyond BPH treatment.

Prostatic urethral lift (PUL / UroLift) — definition

DefinitionProstatic urethral lift (PUL; UroLift) involves placement of permanent UroLift implants to hold open the lateral and median lobes of the prostate and reduce urinary obstruction.

Indication contextFDA‑labeled for symptomatic urinary outflow obstruction due to BPH including lateral with or without median lobe hyperplasia in men ≥45 years.

ContraindicationsContraindicated when prostate volume >100 cc, active UTI, urethral conditions preventing device insertion, urinary incontinence due to incompetent sphincter, or current gross hematuria.

Prostate artery embolization (PAE) — definition

DefinitionProstate artery embolization (PAE) is an endovascular procedure that injects microspheres/particles into prostatic arteries to occlude blood flow, causing prostate shrinkage and symptom relief.

Particle sizes reportedPublished studies report particle sizes in ranges such as 50–500 μm and 250–400 μm used for embolization.

Clinical roleConsidered a minimally invasive option particularly for patients who are poor surgical candidates; evidence shows short‑term benefits but inferior longer‑term functional outcomes versus TURP in some trials.

Focal laser ablation (FLA) — definition

DefinitionFocal laser ablation (FLA) is a percutaneous transperineal laser interstitial therapy that delivers targeted thermal energy to ablate MRI‑visible prostate lesions while sparing surrounding glandular tissue.

Intended useProposed as a focal treatment for localized prostate cancer to treat only tumor tissue rather than whole‑gland therapies.

Evidence statusEvidence is limited to small observational studies and trials; policy considers routine use investigational outside clinical trials due to insufficient long‑term oncologic outcome data.

Prostatic urethral lift (PUL / UroLift) — alternate reference

Procedure recapPUL (UroLift) places permanent implants to hold open prostate lobes and reduce obstruction; FDA‑cleared for men ≥45 years with lateral with or without median lobe hyperplasia.

Contraindication reminderDo not perform PUL when prostate volume >100 cc or other listed contraindications are present.

Coverage notePolicy specifies PUL is proven and medically necessary when performed according to FDA‑labeled indications and absence of contraindications.

Prostatic artery embolization (PAE) — alternate definition and particle sizes

Technique summaryPAE involves endovascular bilateral embolization of prostatic arteries, most commonly via femoral access, using microsphere particles to occlude arterial supply.

Reported particle sizesStudies report particle sizes commonly in ranges such as 50–500 μm or 250–400 μm for embolization procedures.

Clinical considerationPAE may be appropriate for large‑volume prostates and patients with comorbidities making them poor surgical candidates, but comparative evidence versus TURP is limited and shows higher retreatment rates in some RCTs.

Aquablation — robotic, image-guided transurethral waterjet ablation definition

DefinitionAquablation (transurethral waterjet ablation) is a robotic, image‑guided rotating waterjet delivered via a transurethral approach (AquaBeam Robotic System) to ablate prostate tissue with ultrasound/MRI guidance.

Clinical evidenceRCTs compare Aquablation to TURP with outcomes reported up to 5 years; studies include men aged 45–80 with BPH.

IndicationIntended to treat LUTS due to BPH; policy notes it is proven and medically necessary for resection/removal of prostate tissue for LUTS when criteria met.

PAE — further definition (particle sizes and technique)

Procedure detailsPAE is an endovascular occlusion of prostatic arterial supply using embolic particles to reduce prostate blood flow and volume.

Particle size examplesReported particle sizes in trials and series include 50–500 μm and 250–400 μm microspheres.

Outcomes summaryEvidence shows short‑term benefits (less blood loss, shorter hospitalization) but TURP often provides greater long‑term symptom relief; retreatment rates after PAE can be substantial (e.g., ~21% requiring TURP within 2 years in Abt et al.).

TPLA / FLA — definition for transperineal focal laser ablation

DefinitionTransperineal focal laser ablation / Transperineal focal laser ablation (TPLA/FLA) is a percutaneous transperineal, image‑targeted laser energy delivery to ablate MRI‑visible prostate lesions or focal regions of BPH/prostate cancer.

ApproachDelivered via optical fiber through the perineal skin under transrectal ultrasound or MR guidance to target focal lesions while sparing surrounding tissue.

Evidence and policy stanceRCTs and observational studies are limited; policy considers TPLA/FLA investigational for routine use outside clinical trials due to insufficient long‑term oncologic and comparative effectiveness data.

IPSS — definition of International Prostate Symptom Score

DefinitionInternational Prostate Symptom Score (IPSS) is a patient‑reported symptom severity scale commonly used as a primary outcome in BPH trials.

UsageFrequently used in trial eligibility and as a primary outcome to assess symptom improvement after BPH therapies (e.g., PUL, Aquablation, Optilume).

Typical thresholdsTrials often require baseline IPSS thresholds (e.g., ≥10 or ≥13 depending on study).

Qmax — definition of peak urinary flow rate

DefinitionQmax (peak urinary flow rate) is the maximum flow rate measured by uroflowmetry and is an objective measure of urinary obstruction and treatment effect.

Usage in trialsUsed as an objective functional outcome in BPH trials (e.g., PUL, Aquablation, Optilume) with eligibility and efficacy thresholds reported (e.g., Qmax ≤12 mL/s or 5–12 mL/s in some studies).

InterpretationHigher Qmax after treatment indicates improved urinary flow and reduced obstruction.

Optilume — device/system definition

DefinitionOptilume BPH Catheter System is a drug‑coated transurethral balloon catheter system evaluated to reduce LUTS secondary to BPH (EVEREST and PINNACLE studies).

Indication and evidenceStudied in randomized and single‑arm trials in men with symptomatic BPH showing IPSS and Qmax improvements with follow‑up up to 4 years in some cohorts.

Regulatory statusOptilume received FDA clearance (PMA) noted in document for treatment of obstructive urinary symptoms associated with BPH in men ≥50 years.

TULSA — Transurethral Thermal Ultrasound Ablation definition

DefinitionTransurethral Thermal Ultrasound Ablation (TULSA) delivers MRI‑guided transurethral ultrasound energy to thermally ablate prostate tissue with real‑time MR thermometry monitoring.

Intended useInvestigational focal or whole‑gland approach under study for localized prostate cancer and salvage therapy after radiotherapy.

Policy statusAdded to the policy's list of unproven and not medically necessary procedures due to limited comparative evidence and small study sizes.

Device clearance/approval — note on FDA 510(k)/PMA statuses for devices

DefinitionDevice clearance/approval notes: FDA 510(k) clearance or PMA approval status for devices used in prostate procedures is provided for informational purposes only; FDA clearance alone is not a basis for coverage.

ExamplesDevices referenced include UroLift (510[k]), Rezūm (510[k]), Aquabeam (510[k]), Spanner (PMA), iTind (510[k]), and Optilume (PMA).

Provider implicationDevice regulatory status may be documented but does not substitute for meeting policy clinical coverage criteria and medical necessity requirements.

PAE — context: minimally invasive option with tradeoffs

ContextPAE is a minimally invasive alternative for men with moderate‑to‑severe LUTS who accept potentially less optimal efficacy versus TURP in exchange for lower procedural morbidity.

Evidence caveatOverall evidence quality is low to heterogeneous; RCTs suggest shorter‑term benefits but inferior long‑term functional outcomes and higher retreatment rates in some trials.

Operational noteProcedure should be performed in experienced centers and patient selection must consider comorbidities and informed consent about tradeoffs versus TURP.

PAE — policy-described indication for patients ineligible for other procedures

Policy‑described indicationPAE is described in this policy as proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities).

Limited scopePolicy emphasizes use for BPH patients who cannot undergo established surgical therapies (TURP/open prostatectomy) rather than as a routine replacement for TURP in suitable surgical candidates.

Authorization implicationPrior authorization may be required and should document surgical ineligibility, prior medical management, and baseline objective measures (IPSS, Qmax, PVR, prostate volume).

Transurethral water jet ablation — policy clarification on unproven uses

ClarificationTransurethral water jet ablation (Aquablation) is proven and medically necessary for resection/removal of prostate tissue to treat LUTS due to BPH, but is unproven/not medically necessary for malignant prostate tissue and other non‑proven indications.

Evidence noteRCTs comparing Aquablation to TURP report durable improvements up to 5 years in symptom scores and flow measures for appropriately selected patients.

Policy implicationUse outside of BPH indications listed in the policy (e.g., malignant tissue) is considered unproven and not medically necessary due to insufficient safety/efficacy data.

TULSA — added to list of unproven/not medically necessary procedures

Policy updateTULSA was added to the policy's list of unproven and not medically necessary procedures.

Evidence basisPivotal TULSA trials are single‑arm and limited by small numbers and short‑to‑moderate follow‑up; comparative oncologic outcome data are lacking.

Coverage implicationTULSA is considered investigational for routine use and not medically necessary outside of defined investigational settings per policy.

Applicable Codes — Applicable Codes definition and reference

DefinitionApplicable Codes refers to the list of CPT and procedure codes provided in the policy for reference when requesting authorization or billing for prostate surgeries and interventions.

ExamplesPolicy includes codes such as 0421T, 0582T, 0619T, 0655T, 0714T, 0738T, 0739T, 0867T, 37243, 51721, 52441, 52442, 53865, 53866, 53850, 53852, 53854, 53855, 55873, 55881, 55882 among others as listed in the Applicable Codes sections.

Operational noteInclusion of codes in the Applicable Codes list is for reference only and does not guarantee coverage; benefit determination depends on medical necessity and contract terms.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information.

2026-05-01archive

Archived previous policy version CS334ID.A while updating supporting sections.

2026-05-01applicable_codes_updateLatest

Applicable CPT codes list updated (added 51721, 53865, 53866, 55881, 55882 and removed 55874) as the final applied code changes.

2026-05-01version_archivedLatest

Archived prior policy version CS334ID.A during the policy update process.